跳至主要内容
临床试验/PACTR201908498370196
PACTR201908498370196已完成未知

Metformin versus Levonorgestrel-Releasing Intrauterine Device (MIRENA) in the Management of Endometrial Hyperplasia

faculty of medicine suez canal university0 个研究点目标入组 50 人开始时间: 2019年8月21日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
Female

入选标准

  • 1-Women between the ages of 18-75 years old.
  • 2-Women with a histological diagnosis of endometrial hyperplasia without atypia confirmed by endometrial biopsy.

排除标准

  • 1-Pregnant women.
  • 2-Women with contraindication to Metformin (Impaired renal functions , Cirrhosis of the liver, Hepatitis and Alcoholism).
  • 3-Women with contraindications to Mirena (e.g. acute genital tract inflammatory disease, genital bleeding of unknown etiology, hypersensitivity to any component of this product, congenital or acquired uterine anomaly, known or suspected breast cancer, known or suspected uterine and cervical neoplasia or acute liver disease or liver tumor).
  • 4-Women with concurrent endometrial cancer .
  • 5-Women with a history of a hormone-dependent malignancy (e.g. breast cancer).
  • 6-Women taking tamoxifen.

研究者

相似试验